This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

BioNTech SE
11/3/2026
Welcome to Biontech's third quarter 2026 earnings call. I will now hand the call over to Douglas Maffei, Vice President of Investor Relations. Please go ahead.
Thank you, operator. Good morning and good afternoon, everyone. Thank you for joining Biontech's third quarter 2026 earnings call. As a reminder, the slides we will use during this call and the corresponding press release can be found in the investor section of our website. Please also note we will refer to both IFRS and adjusted non-IFRS financials. Our earnings release materials include reconciliation of the adjusted results to the most directly comparable measures based on IFRS accounting standards. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the US Securities and Exchange Commission, or SEC. Forward-looking statements on this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements. On slide three, you can find the agenda for today's call. I'm joined by the following members of BuyOnTech's management team. Ugur Sahin, chief executive officer and co-founder, Ozlem Tureci, chief medical officer and co-founder, and Ramon Zapata, chief financial officer. Also available for the Q&A portion of the call is Annemarie Hanekamp, chief commercial officer. With this, I'll hand the call over to Ugur.
Thank you Doug, a warm welcome to everyone joining us today. We have made good progress against our strategic milestones set out for 2026, reflecting our continued commitment to advancing our pipeline. First, we are accelerating the late-stage development of our oncology assets. At the World Conference on Lung Cancer in September, we presented updated overall survival data for Gryptobacter from the non-pivotal stage of our global phase 3 trial in patients with squamous non-small cell lung cancer who progressed on prior checkpoint inhibitor treatment. Gotistobar nearly doubled median overall survival compared to standard of care chemotherapy. This is a setting where chemotherapy has remained the standard of care for more than a decade, and with Gotistobar, we aim to provide a chemotherapy-free monotherapy for patients who progressed after first-run therapy. They are encouraged by the data and the pivotal stage of the trial is ongoing. Second, our combination therapy strategy continues to gain momentum. We recently entered into a clinical trial collaboration and supply agreement with Gilead to evaluate Pumitami in combination with their top two directed antibody drug conjugate as first-line treatment for patients with metastatic PD-L1 low or negative triple negative breast cancer. If approved by regulators, this would be the first Phase III trial of Promethamine in combination with an antibody drug conjugate and an important milestone in advancing our combination therapy strategy towards registration. Third, we continue our shift from a platform-centric to a tumor-centered clinical development approach in cancers with the greatest unmet medical need. At the World Lung Congress, who presented the first global combination data for any anti-PD-L1 VGF biospecific immunomodulator and an ADC in lung cancer. This combination of Prometamic and LVD demonstrated encouraging early efficacy and manageable safety profile in small cell lung cancer, the cost lines of treatment including activity in first-time patients. This data are the sickness-seeking evidence we set out to generate this year. The observed clinical responses are encouraging and speak to the potential of novel-novel combinations in lifting survival curves. These data we have seen support our phase 3 registrational planning for Prometamic in combination with LVD. Looking ahead, BioNTech is well positioned for the next phase of growth. With a growing pipeline of potentially registrational trials, strong partnerships, and financial strength, We are on track to become a diversified multi-product company by 2030. Our latest state development program includes multiple pivotal types readouts to 2030 and beyond, spanning multiple tumor types and different lines of treatment. As we announced last quarter, Guido Oelkers will take office as CEO by 1st February at latest. I am confident that he will bring in his valuable experience to continue advancing BioNTech's unique and strong pipeline. Management and Supervisory Board members have been actively engaged in supporting a seamless transition. We have built BioNTech from a startup into a global biopharmaceutical company with a strong foundation across next-generation immunomodulators, ADCs, and messenger RNA. We have also established a distinguished combination therapy strategy in oncology. At the heart of our work is a shared purpose, advancing medical innovation to improve patient life. Our employees have been instrumental in bringing this purpose to life with their expertise, dedication, and commitment. It is their collective contribution that has turned scientific discovery into meaningful progress for humanity and better outcomes for patients. We see significant potential in BioNTech. As this will be my last earnings call, I would like to thank the many exceptional and dedicated BioNTech team members and leaders, the management and the supervisory board, our founding partners, shareholders, and collaborators. I would also like to thank the patients, investigators, and other healthcare professionals who have been contributing to our trials and our colleagues in the science community. Without all the contributors, none of this would have been possible. The impact we have created together to bring full innovation For science, medicine and patients is something I will look back on this deep gratitude. While we hand over the operational responsibility to our successors, Özlem and I will continue to follow BioNTech as founding shareholders. With this, I will hand over to Özlem.
You're reading a preview of the BNTX Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing